(R)-2-chloro-1-(5-fluoropyridin-3-yl)ethan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (R)-2-chloro-1-(5-fluoropyridin-3-yl)ethan-1-ol
• 英文别名: (1R)-2-chloro-1-(5-fluoropyridin-3-yl)ethanol
• 化学式: C₇H₇ClFNO
• 分子量: 175.59
• InChiKey: LXXUKJNREGMSGZ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-chloro-1-(5-fluoropyridin-3-yl)ethan-1-ol 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 异丙醇 为溶剂， 反应 4.0h， 生成 (R)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)ethan-1-ol oxalate
  参考文献：
  名称：

  [EN] CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2
  [FR] FORME CRISTALLINE DU SEL HÉMI-TARTRATE DE (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ÉTHAN-1-OL POUR LE TRAITEMENT DE L'HYPERGLYCÉMIE ET DU DIABÈTE DE TYPE 2

  摘要：

  The present invention discloses a crystalline form of the (R)-2-(tert- butylamino)-1-(5-fluoropyridin-3-yl)ethanol (formula (I)) hemi-(2R,3R) -tartrate salt characterised by a melting point of 211 °C and the XRPD pattern of figure 1. The present invention also relates to said hemi-tartrate salt for use in the treatment of hyperglycaemia and type 2 diabetes through activation of the beta2-adrenergic receptor. Importantly, such salts are thought to have a beneficial side-effect profile as they do not exert their effect through significant cAMP release.

  公开号：

  WO2023105035A1
• 作为产物：
  描述：

  2-chloro-1-(5-fluoropyridin-3-yl)ethan-1-one hydrochloride 在 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 三乙胺 、 (1S,2S)-(+)-N-对甲苯磺酰基-1,2-二苯基乙二胺 作用下， 以 醋酸异丙酯 为溶剂， 以72 %的产率得到(R)-2-chloro-1-(5-fluoropyridin-3-yl)ethan-1-ol
  参考文献：
  名称：

  [EN] CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2
  [FR] FORME CRISTALLINE DU SEL HÉMI-TARTRATE DE (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ÉTHAN-1-OL POUR LE TRAITEMENT DE L'HYPERGLYCÉMIE ET DU DIABÈTE DE TYPE 2

  摘要：

  The present invention discloses a crystalline form of the (R)-2-(tert- butylamino)-1-(5-fluoropyridin-3-yl)ethanol (formula (I)) hemi-(2R,3R) -tartrate salt characterised by a melting point of 211 °C and the XRPD pattern of figure 1. The present invention also relates to said hemi-tartrate salt for use in the treatment of hyperglycaemia and type 2 diabetes through activation of the beta2-adrenergic receptor. Importantly, such salts are thought to have a beneficial side-effect profile as they do not exert their effect through significant cAMP release.

  公开号：

  WO2023105035A1

文献信息

• [EN] HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA<br/>[FR] BÊTA-HYDROXYÉTHYLAMINO SUBSTITUÉES PAR HÉTÉROARYLE DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE L'HYPERGLYCÉMIE
  申请人：ATROGI AB

  公开号：WO2019053427A1

  公开（公告）日：2019-03-21

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

  本文提供了一个式(I)的化合物或其药用可接受的盐，其中环含有Q1至Q5，以及基团R1、R2和R3的含义如描述中所提供。
• Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
  申请人：ATROGI AB

  公开号：US11357757B2

  公开（公告）日：2022-06-14

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

  本文提供了式 (I) 的化合物或其药学上可接受的盐，其中含有 Q1 至 Q5 的环以及基团 R1、R2 和 R3 的含义如描述中所提供。
• HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA
  申请人：Atrogi AB

  公开号：EP3681872B1

  公开（公告）日：2021-11-17
• BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING
  申请人：[en]ATROGI AB

  公开号：WO2024153813A1

  公开（公告）日：2024-07-25

  There is herein provided a 2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease or disorder characterised by muscle wasting.